64 filings
Page 2 of 4
8-K
5wamhhb0
14 Apr 23
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
4:08pm
8-K
v24p41p
8 Feb 23
23andMe Reports FY2023 Third Quarter Financial Results
4:09pm
8-K
hweqy6xxsntle7g6222
6 Feb 23
Other Events
4:53pm
8-K
ixp4w0 shvyu
9 Dec 22
Departure of Directors or Certain Officers
8:05am
8-K
ap2rg2nrxibsi1y4
9 Nov 22
Investor Presentation November 2022
7:30am
8-K
yp4lfky8e4h8rtvy
7 Nov 22
23andMe Reports FY2023 Second Quarter Financial Results
4:06pm
8-K
ju5fsq
4 Nov 22
Other Events
4:06pm
8-K
0a4ud 1w2a
27 Oct 22
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication
7:32am
8-K
zopwrnr5t
31 Aug 22
Submission of Matters to a Vote of Security Holders
7:13pm
8-K/A
ipfb9klwk5q
30 Aug 22
Departure of Directors or Certain Officers
4:05pm
8-K
slpruxw
19 Aug 22
Departure of Directors or Certain Officers
8:02am
8-K
o69hpjgq9
18 Aug 22
Investor Presentation August 2022
4:06pm
8-K
9pc371wpo
8 Aug 22
23andMe Reports FY2023 First Quarter Financial Results
4:14pm
8-K
394qpk6 dbmouc8y3md
13 Jun 22
Departure of Directors or Certain Officers
4:05pm
8-K
vnxs6txa789riw8le
26 May 22
23andMe Reports FY2022 Fourth Quarter and Full Year Financial Results
4:02pm
8-K
wui6g
13 Apr 22
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
4:57pm
8-K
5lwtyrf2
23 Feb 22
Regulation FD Disclosure
9:31am
8-K
rdifw
10 Feb 22
23andMe Reports FY2022 Third Quarter Financial Results
4:11pm
8-K
cje 70rkq
18 Jan 22
Regulation FD Disclosure
8:15am
8-K
thaofl be2c
10 Jan 22
23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker
8:16am